Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients

International Journal of Clinical Oncology

Volumn 14, Issue 2, 2009, Pages 130-135

  Soga, Norihito ^a   Kato, Manabu ^a   Nishikawa, Kouhei ^a   Hasegawa, Yoshihiro ^a   Yamada, Yasushi ^a   Kise, Hideaki ^a   Arima, Kiminobu ^a   Sugimura, Yoshiki ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel Estramustine; HRPC; Intermittent

Indexed keywords

ANDROGEN; CREATININE; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ANDROGEN THERAPY; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; HUMAN; JAPANESE; LIVER DYSFUNCTION; MALE; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TAXOIDS;

EID: 65349124963     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0814-y     Document Type: Article

References (21)

1. D.P. Petrylak C.M. Tangen M.H. Hussain 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513 1520 (Pubitemid 39315318)
2. I.F. Tannock R. de Wit W.R. Berry 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502 1512 (Pubitemid 39315317)
3. T.M. Beer M. Garzotto W.D. Henner 2004 Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer Br J Cancer 91 1425 1427 (Pubitemid 39486342)
4. T.M. Beer M. Garzotto W.D. Henner 2003 Intermittent chemotherapy in metastatic androgen-independent prostate cancer Br J Cancer 89 968 970 (Pubitemid 37239196)
5. T.M. Beer C.W. Ryan P.M. Venner 2008 Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel Cancer 112 326 330
6. Arbuck SG, Ivy SP, Setser A, et al. The revised Common Toxicity Criteria, Version 2.0 Cancer Therapy Evaluation website. http://ctep.info.nih.gov
7. N.K. Aaronson S. Ahmedzai B. Bergman 1993 The European Organisation for Research and Treatment of Cancer QLQC-30 Aquality-of-life instrument for use in intenational clinical trials in oncology J Natl Cancer Inst 85 365 376 (Pubitemid 23073154)
8. L. Beex C. Rose H. Mouridsen 2006 Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863) Eur J Cancer 42 3178 3185
9. A.M. Lin C.J. Ryan E.J. Small 2007 Intermittent chemotherapy for metastatic hormone refractory prostate cancer Crit Rev Oncol Hematol 61 243 254 (Pubitemid 46329430)
10. T.M. Beer K.M. Eilers M. Garzotto 2004 Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma Cancer 100 758 763 (Pubitemid 38176854)
11. A. Takenaka Y. Yamada T. Kurahashi 2008 Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients Int J Urol 15 106 109
12. D. Savarese M.E. Taplin S. Halabi 1999 A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B Trial 9780 Semin Oncol 26 39 44 (Pubitemid 30000744)
13. V.J. Sinibaldi M.A. Carducci S. Moore-Cooper 2002 Phase II evaluation of docetaxel plus 1-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma Cancer 94 1457 1465 (Pubitemid 34212640)
14. S. Oudard E. Banu P. Beuzeboc 2005 Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer J Clin Oncol 23 3343 3351 (Pubitemid 46243478)
15. A. Font A. Murias F.R. Arroyo 2005 Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study Ann Oncol 16 419 424 (Pubitemid 40458318)
16. C.M. Perry D. McTavish 1995 Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer Drugs Aging 7 49 74
17. K.D. Tew M.E. Stearns 1989 Estramustine - a nitrogen mustard/steroid with antimicrotubule activity Pharmacol Ther 43 299 319 (Pubitemid 19218851)
18. T. Kitamura 2001 Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer Int J Urol 8 33 36 (Pubitemid 32245339)
19. W. Kreis D.R. Budman J. Fetten 1999 Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma Ann Oncol 10 33 38 (Pubitemid 29090589)
20. D. Friedland J. Cohen R. Miller 1999 A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2 Semin Oncol 26 19 23 (Pubitemid 30000740)
21. K. Nishimura N. Nonomura Y. Yasunaga 2000 Low doses of oral dexamethasone for hormone-refractory prostate carcinoma Cancer 89 2570 2576 (Pubitemid 32011601)